Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma

Recommendation ID: IPG630/2
Question: Clinicians should enter details about all patients having selective internal radiation therapy (SIRT) for unresectable primary intrahepatic cholangiocarcinoma onto a suitable registry.
Any explanatory notes (if applicable): Current evidence on the safety of selective internal radiation therapy (SIRT) for unresectable primary intrahepatic cholangiocarcinoma shows that there are well-recognised, serious but rare safety concerns. Evidence on its efficacy is inadequate in quantity and quality. Therefore, this procedure should only be used in the context of research.

Source guidance details

Comes from guidance: Selective internal radiation therapy for unresectable primary intrahepatic cholangiocarcinoma
Number: IPG630
Date issued: October 2018

Is this a recommendation for the use of a technology only in the context of research?	No
Is it a recommendation that suggests collection of data or the establishment of a register?	Yes
Last Reviewed	31/10/2018